MD Anderson Cancer Center, Houston: International Patient Guide

Founded in 1941, MD Anderson combines cancer treatment, research, education and prevention. Its main clinical operations are in Houston’s Texas Medical Center, with additional locations serving the wider region. International patients should confirm which location will provide each part of their assessment or treatment.

The institution holds comprehensive cancer centre designation from the US National Cancer Institute. This recognises the breadth of its research, including laboratory, clinical and population-based work. The designation describes institutional capabilities; it is not a guarantee of treatment benefit or an individual outcome.

MD Anderson operates at a very high case volume and organises much of its care through disease-specific multidisciplinary teams. Depending on the case, these may involve medical oncologists, surgeons, radiation oncologists, pathologists and other specialists. It is particularly known for complex cancer care, a large phase I programme and a dedicated proton therapy centre. Its scale also means that assessment may involve several departments rather than a single consultation.

Disease-focused programmes cover liver, lung, breast, colon and prostate cancers. Assessment considers the tumour’s origin, stage, pathology and relevant molecular findings. For liver tumours, distinguishing primary liver cancer from cancer that has spread to the liver is essential. Colorectal care also requires attention to differences between colon and rectal cancer, which can change treatment planning.

Blood cancer services address conditions such as leukaemia, lymphoma and myeloma, with treatment pathways that may include cellular therapy or stem cell transplantation. Rare cancer programmes include specialist assessment of less common tumour types, such as sarcomas, where expert pathology review can be important. Across these services, recurrent disease, unusual diagnoses and complex treatment decisions may prompt multidisciplinary review. The existence of a programme does not mean that every patient will need treatment at the centre or qualify for an experimental option.

Surgery is available across numerous cancer types, with suitability determined by tumour location, spread, operability and the patient’s fitness. Surgical planning may involve reconstruction and rehabilitation. Radiation options include external-beam treatment and, for appropriate indications, other specialised techniques. The centre also has a proton therapy facility; proton treatment is not automatically preferable to conventional radiation and requires a case-specific assessment.

Systemic treatment includes chemotherapy, hormonal therapy, immunotherapy and targeted medicines. Some treatments require particular biomarkers, while others depend primarily on the cancer type and stage. Immunotherapy can cause significant immune-related side effects, and targeted treatment is useful only when the tumour and clinical evidence support its use.

Precision oncology uses molecular and other diagnostic information to help refine treatment choices. Testing may identify an established treatment, suggest a trial or find no actionable result. Patients should ask whether existing test results can be used and whether additional tissue or blood testing is necessary.

CAR-T cell therapy is available for selected indications, particularly certain blood cancers. Assessment includes previous treatments, organ function and the ability to remain near the centre for monitoring. Manufacturing, treatment preparation and follow-up can affect the schedule. Supportive care, symptom management and rehabilitation may accompany any treatment pathway.

MD Anderson has a broad oncology trial portfolio spanning early drug development and later-phase studies. An indicative figure of around 1,400 active oncology clinical trials conveys its scale, but should not be read as a verified current recruitment count. Active studies can include trials closed to new enrolment. The large phase I programme evaluates investigational approaches, often with a primary focus on safety and dose; benefit is uncertain.

International patients can ask for trial consideration during specialist assessment. Eligibility may depend on pathology, biomarkers, prior medicines, organ function, functional status and an available place. A study listing alone does not confirm access. Before travelling, ask about screening requirements, repeat visits, language arrangements, financial responsibility and whether follow-up can occur locally. Trial participation is voluntary and requires informed consent.

Begin with Global Patient Services or the centre’s official appointment pathway and provide a concise clinical summary. Ask whether records can be reviewed before travel, what that review can establish and whether an in-person assessment is required. Do not assume an enquiry or appointment confirms a specific treatment or trial place. Avoid delaying time-sensitive local care while awaiting arrangements.

Request an individual financial estimate and clarify insurance authorisation, payment requirements and what could change the estimate. Plan for a caregiver, accommodation, transport and possible schedule changes. Confirm any medical travel documentation needed, without assuming that acceptance guarantees a visa. Before returning home, obtain a treatment summary, medicine plan, emergency instructions and an agreed handover to the local oncology team.

Contact details below come from the hospital's own published international patient information.

Location: Houston, United States

Email: informationline@mdanderson.org

Phone: +1 713 792 3245

Website: https://www.mdanderson.org

Languages supported: English, Spanish, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.